Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
about
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Cost-effectiveness analysis of ...... erienced HIV-positive patients
@ast
Cost-effectiveness analysis of ...... erienced HIV-positive patients
@en
type
label
Cost-effectiveness analysis of ...... erienced HIV-positive patients
@ast
Cost-effectiveness analysis of ...... erienced HIV-positive patients
@en
prefLabel
Cost-effectiveness analysis of ...... erienced HIV-positive patients
@ast
Cost-effectiveness analysis of ...... erienced HIV-positive patients
@en
P2093
P2860
P50
P356
P1476
Cost-effectiveness analysis of ...... erienced HIV-positive patients
@en
P2093
Giuliano Rizzardini
Marzia Bonfanti
Umberto Restelli
P2860
P304
P356
10.2147/TCRM.S135972
P577
2017-06-29T00:00:00Z